The Johns Hopkins University

Other

Zhiyong Yang

Donald Jeffrey Zack

Cynthia Ann Berlinicke

Tomas Vojkovsky

Derek Stuart Welsbie

Justin Scot Hanes

Thomas D Bannister

Jie Fu

Harry Quigley

Barbara S Slusher

Joseph P Steiner

Dana Victor Ferraris

James Inglese

Laszlo Hackler

Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or other inhibitors of JNK signaling, which bind to DLK. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or reduce neuronal death due to elevated intraocular pressure. Upon administration, the sunitinib or other inhibitor is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity, and which provide much longer release than inhibitor without conjugate.

Sunitinib formulations and methods for use thereof in treatment of glaucoma

Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

Compositions and methods for treatment of neurodegenerative disease

Compounds and methods of use thereof for treating neurodegenerative disorders

Growing community of inventors

Baltimore, MD, United States of America

Zhiyong Yang